Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:CE 25:4)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003988 AN006569 Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to RTK targeting and immunologically active Cultured cells Human Cancer CNRS LC-MS
ST000148 AN000235 A549 13C-labeled Cell Study Epithelial cells Human Cancer University of Kentucky LC-MS
  logo